Table 3.
Summary of the meta-analysis results.
| Categories | Trials | HR (95% CI) | I 2 (%) | P H | Z | P z | P m |
|---|---|---|---|---|---|---|---|
| Pretreatment | 11 (7398) | 2.56 (1.78-3.68)R | 71.5 | <0.001 | 5.06 | <0.001 | |
| Study region | 0.245 | ||||||
| Taiwan | 3 (2256) | 2.71 (1.78-4.12) | 10.4 | 0.327 | 4.67 | <0.001 | |
| Korea | 5 (4084) | 2.80 (1.44-5.46)R | 86.4 | <0.001 | 3.03 | 0.002 | |
| Others | 3 (1058) | 1.90 (1.23-2.93) | 0.0 | 0.657 | 2.91 | 0.004 | |
| Hepatitis type | 0.542 | ||||||
| CHB | 5 (3586) | 3.16 (1.77-5.63)R | 67.1 | 0.016 | 3.89 | <0.001 | |
| CHC | 5 (2888) | 2.17 (1.42-3.32)R | 57.9 | 0.050 | 3.56 | <0.001 | |
| ALC | 1 (924) | 1.46 (0.73-2.94)R | NA | NA | 1.06 | 0.287 | |
| Cut-off value | 0.600 | ||||||
| ≥1.0 | 5 (2461) | 1.62 (1.35-1.95) | 36.8 | 0.176 | 5.15 | <0.001 | |
| <1.0 | 5 (4251) | 3.79 (2.15-6.67)R | 55.7 | 0.060 | 4.61 | <0.001 | |
| NR | 1 (686) | 2.04 (1.10-3.79)R | NA | NA | 2.26 | 0.024 | |
| Sample size | 0.643 | ||||||
| ≥800 | 5 (5095) | 2.79 (1.76-4.42)R | 52.2 | 0.079 | 4.35 | <0.001 | |
| <800 | 6 (2303) | 2.37 (1.36-4.13)R | 77.2 | 0.001 | 3.03 | 0.002 | |
| Analysis method | 0.373 | ||||||
| Multivariate | 7 (4873) | 2.37 (1.82-3.09) | 41.2 | 0.116 | 6.36 | <0.001 | |
| Univariate | 4 (2525) | 2.90 (1.30-6.46)R | 86.3 | <0.001 | 2.60 | 0.009 | |
| Posttreatment | 5 (2884) | 3.69 (2.52-5.42) | 7.8 | 0.362 | 6.68 | <0.001 |
CHB: chronic hepatitis B; CHC: chronic hepatitis C; ALC: alcoholic liver cirrhosis; NR: none reported; PH: P value for heterogeneity based on the Q test; PZ: P value for statistical significance based on the Z test; Pm: P value for statistical outcome based on multivariate metaregression analysis; R: random-effect model.